Financial News

Nicox Initiates Phase 2 Study of NCX 470 in Open-Angle Glaucoma and Ocular Hypertension

  • Study to randomize 420 patients in clinical sites across the U.S.
  • Top-line results expected H2 2019
  • Targets $5 billion worldwide glaucoma market1

Sophia Antipolis, France / Research Triangle Park, NC, United States
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the initiation of a Phase 2 clinical study evaluating NCX 470,

Read more

Nicox Second Quarter 2018 Business Update and Financial Highlights

release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided operational highlights and upcoming milestones, as well as revenues and cash position for Nicox and its subsidiaries (the “Nicox Group”) as of June 30, 2018. Michele Garufi, Chairman and Chief Executive Officer of Nicox, stated,…

Read more

Nicox Highlights Recent Progress with Key Programs and Activities

Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a business update and highlighted recent progress with key programs and activities.
As expected, the first half of 2018 has seen important progress with our primary research and development projects,” said Michele Garufi, Chairman and Chief Executive Officer of Nicox.

Read more
More news